Aliskiren accumulates in renin secretory granules and binds plasma prorenin

Hypertension

Volumn 52, Issue 6, 2008, Pages 1076-1083

  Krop, Manne ^a   Garrelds, Ingrid M ^a   De Bruin, René J A ^a   Van Gool, Jeanette M G ^a   Fisher, Naomi D L ^b   Hollenberg, Norman K ^b   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aliskiren; Mast cell; Prorenin; Renin; Storage granule

Indexed keywords

ALISKIREN; FORSKOLIN; PRORENIN;

ARTICLE; BLOOD SAMPLING; CELL LYSATE; CONCENTRATION (PARAMETERS); CULTURE MEDIUM; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; MAST CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SECRETORY GRANULE;

AMIDES; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENTS; CELL LINE, TUMOR; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; FUMARATES; HUMANS; LEUKEMIA, MAST-CELL; MAST CELLS; RENIN; SECRETORY VESICLES;

EID: 57449100853     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.123042     Document Type: Article

References (28)

1. Kitami Y, Hiwada K, Murakami E, Muneta S, Kokubu T. The effect of the renin inhibitor ES-1005 on the expression of the kidney renin gene in sodium-depleted marmosets. J Hypertens. 1990;8:1143-1146.
2. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daughterly A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
3. Ii Y, Murakami E, Hiwada K. Effect of renin inhibitor, ES-8891, on renal renin secretion and storage in the marmoset: comparison with captopril. J Hypertens. 1991;9:1119-1125.
4. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007;20:587-597.
5. Azizi M, Bissery A, Lamarre-Cliche M, Ménard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004;43:785-790.
6. Batenburg WW, de Bruin RJA, van Gool JMG, Müller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1151-1157.
7. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem. 1992;267:22837-22842.
8. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46:1069-1076.
9. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, Müller DN, Bader M, Nguyen G, Danser AHJ. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens. 2007;25:2441-2453.
10. Ménard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006;24:529-534.
11. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.
12. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589-599.
13. Feldman D, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Danser AHJ, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)-27 rats. Hypertension. 2008;52:130-136.
14. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology. 2007;22:310-319.
15. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101:13607-13612.
16. Krop M, Garrelds IM, Danser AHJ. Renin and prorenin release by human mast cells [abstract]. J Hypertens. 2007;25:S12.
17. Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol. 2001;280:H1706-H1715.
18. Hara M, Ono K, Wada H, Sasayama S, Matsumori A. Preformed angiotensin II is present in human mast cells. Cardiovasc Drugs Ther. 2004;18:415-420.
19. Fisher NDL, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-3205.
20. van Kesteren CAM, Saris JJ, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II. Cardiovasc Res. 1999;43:148-156.
21. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MADH, Danser AHJ. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res. 1999;44:407-415.
22. Saris JJ, van den Eijnden MMED, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. Prorenin-induced myocyte proliferation: no role for intracellular angiotensin II. Hypertension. 2002;39:573-577.
23. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens. 1998;16:853-862.
24. Ohtsu H. Progress in allergy signal research on mast cells: the role of histamine in immunological and cardiovascular disease and the transporting system of histamine in the cell. J Pharmacol Sci. 2008;106:347-353.
25. Taugner R, Whalley A, Angermuller S, Buhrle CP, Hackenthal E. Are the renin-containing granules of juxtaglomerular epithelioid cells modified lysosomes? Cell Tissue Res. 1985;239:575-587.
26. Peters J, Clausmeyer S. Intracellular sorting of renin: cell type specific differences and their consequences. J Mol Cell Cardiol. 2002;34:1561-1568.
27. van den Eijnden MMED, Saris JJ, de Bruin RJA, de Wit E, Sluiter W, Reudelhuber TL, Schalekamp MADH, Derkx FHM, Danser AHJ. Prorenin accumulation and activation in human endothelial cells. Importance of mannose 6-phosphate receptors. Arterioscler Thromb Vasc Biol. 2001;21:911-916.
28. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.